Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve~* Age 18 and older than 18 years old~* Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive \> 6 months~* Detectable serum quantitative HCV-RNA (Cobas Amplicor HCV Monitor v2.0, Roche Molecular Systems, Pleasanton, CA) with dynamic range 600\~\<500,000 IU/ml~* HCV genotype 1 (Inno-LiPA HCV II, Innogenetics, Ghent, Belgium)~* Serum alanine aminotransferase levels above the upper limit of normal with 6 months of enrollment~* A liver biopsy consistent with the diagnosis of chronic hepatitis C~Exclusion Criteria:~* Anemia (hemoglobin \< 13 gram per deciliter for men and \< 12 gram per deciliter for women)~* Neutropenia (neutrophil count \<1,500 per cubic milliliter)~* Thrombocytopenia (platelet \<90,000 per cubic milliliter)~* Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Chronic alcohol abuse (daily consumption \> 20 gram per day)~* Decompensated liver disease (Child-Pugh class B or C)~* Serum creatinine level more than 1.5 times the upper limit of normal~* Autoimmune liver disease~* Neoplastic disease~* An organ transplant~* Immunosuppressive therapy~* Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus~* Evidence of drug abuse~* Unwilling to have contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginterfron and ribavirin (24 weeks) (Type: ACTIVE_COMPARATOR): Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
- Peginterferon and ribavirin (48 weeks) (Type: ACTIVE_COMPARATOR): Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).